Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients
https://doi.org/10.22416/1382-4376-2017-27-5-65-68
Abstract
About the Authors
D. T. AbdurakhmanovRussian Federation
Ye. . Sidorova
Russian Federation
I. N. Tikhonov
Russian Federation
N. A. Mukhin
Russian Federation
V. T. Ivashkin
Russian Federation
References
1. Всемирная организация здравоохранения. Глобальное предупреждение и ответные действия (GAR). Hepatitis C. 2012 (http://www.who.int/csr/disease/ hepatitis/ whocdscsrlyo2003/en/index4.html).
2. Breitenfeldt M., Rasenack J., Berthold H. et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16:130-6.
3. Neumann U., Berg T., Bahra M. et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-31.
4. Doucette K.E., Halloran K., Kapasi A., Lien D., Weinkauf J.G. Outcomes of lung transplantation in recipients with hepatitis C virus infection. Am J Transplant 2016; 16:2445-52.
5. Sahi H., Zein N., Mehta A., Blazey H., Meyer K., Budev M. Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J Heart Lung Transplant 2007; 26:466-71.
6. Garcha P., Fadul R., Kapoor A. et al. Long-Term Outcomes of Lung Transplantation (LT) in Hepatitis C Positive (HCVþ) Patients. J Heart Lung Transplant 2013; 32:4S, A108.
7. Koenig A., Stepanova M., Saab S., Ahmed A., Wong R., Younossi Z.M. Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. Aliment Pharmacol Ther 2016; 44:271-8.
8. Carreno M., Piedad U., Maite L. et al. Hepatitis C virus infection after lung transplantation: Dim prognosis. J Heart Lung Transplant 2001; 20:224.
9. Manns M., Pol S., Jacobson I. et al; HALLMARK- DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384:1597-605.
10. Ueda Y., Kaido T., Hatano E., Ohtsuru S., Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatol Res 2015; 45:1360-2.
11. Ozaras R., Mete B., Yemisen M., Balkan I., Alkan M., Tabak F. Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir (letter to editor). J Gastrointest Liver Dis 2015; 24:393-4.
12. Kumada H., Suzuki Y., Ikeda K. et al. Daclatasvir plus asunaprevir for chronic hcv genotype 1b infection. Hepatology 2014; 59:2083-91.
13. Doucette K., Sumner S., Weinkauf J. Treatment of hepa- titis C in a lung transplant recipient with sofosbuvir and daclatasvir. J Heart Lung Transplant 2016; 35(6):840-1.
14. D’Ambrosio R., Aghemo A., Rossetti V., Carrinola R., Colombo M. Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature. Liver International 2016; 1-5. DOI: 10.1111/liv.13203
15. Weill D., Benden C., Corris P.A. et al. A consensus document for the selection of lung transplant candidates: 2014 - An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1-15.
16. Ueda Y., Uemoto S. Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. Transplant International 2016; 29:119-21.
Review
For citations:
Abdurakhmanov D.T., Sidorova Ye., Tikhonov I.N., Mukhin N.A., Ivashkin V.T. Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):65-68. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-5-65-68